July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.
January 2021 in “Journal of the European Academy of Dermatology and Venereology” PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
September 2025 in “JAAD reviews.” Finasteride and dutasteride can improve hair loss in women, but more research is needed.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
January 2020 in “The Journal of Sexual Medicine” Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
63 citations
,
December 2013 in “PLoS ONE” Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
23 citations
,
September 2020 in “BMC Cancer” 5α-reductase inhibitors may lower the risk of death from bladder cancer.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
19 citations
,
June 2017 in “Asian journal of urology” Family doctors can manage older men with urinary symptoms using exams, tests, and medications.
5 citations
,
December 2024 in “Archivio Italiano di Urologia e Andrologia” Personalized treatment is crucial for effectively managing benign prostatic hyperplasia (BPH).
4 citations
,
December 2021 in “Archivio italiano di urologia andrologia” Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
2 citations
,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
1 citations
,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.